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Mycobacterium tuberculosis (Mtb) is the etiological agent of tuber-
culosis. One-fourth of the global population is estimated to be in-
fected with Mtb, accounting for ∼1.3 million deaths in 2017. As part
of the immune response to Mtb infection, macrophages produce
metabolites with the purpose of inhibiting or killing the bacterial
cell. Itaconate is an abundant host metabolite thought to be both an
antimicrobial agent and a modulator of the host inflammatory re-
sponse. However, the exact mode of action of itaconate remains
unclear. Here, we show that Mtb has an itaconate dissimilation
pathway and that the last enzyme in this pathway, Rv2498c, also
participates in L-leucine catabolism. Our results from phylogenetic
analysis, in vitro enzymatic assays, X-ray crystallography, and in
vivo Mtb experiments, identified Mtb Rv2498c as a bifunctional
β-hydroxyacyl-CoA lyase and that deletion of the rv2498c gene from
the Mtb genome resulted in attenuation in a mouse infection
model. Altogether, this report describes an itaconate resistance
mechanism in Mtb and an L-leucine catabolic pathway that proceeds
via an unprecedented (R)-3-hydroxy-3-methylglutaryl-CoA (HMG-
CoA) stereospecific route in nature.
enzyme function | carbon–carbon bond lyase | Mycobacterium
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Mycobacterium tuberculosis (Mtb) is the etiological agent oftuberculosis (TB). In 2017, an estimated 10 million people
developed TB and around 1.3 million people died from the
disease; it is thought that up to one-fourth of the global pop-
ulation is infected with Mtb (1, 2). The pathogenicity, physio-
logical resiliency and plasticity of Mtb are notably complex, with
humans serving as their main reservoir, highlighting the effect of
niche adaptation on pathogen evolution (3, 4). Despite the
medical impact of TB, Mtb biology remains largely unexplored,
and over half of the enzymes in the proteome lack a defined
catalytic activity (5, 6). To date, delineating the in vivo functional
roles of hundreds of poorly characterized enzymes has been a
significant challenge (7). This difficulty is in part due to the
unconventional nutrient assimilation of Mtb and its ability to
persist in different metabolic states (8–11). Without an adequate
understanding of the fundamental biology underpinning in-
fection and the associated metabolic networks, we continue to
generate drug candidates that fail in eradicating the pathogen.
Moreover, our knowledge of the exact cellular and molecular
mechanisms by which the immune system eradicates Mtb or fails
to do so remains incomplete. Thus, a deeper understanding of
the Mtb biology and its interaction with the host is pivotal to
tackle the TB pandemic.
Itaconate is produced by the mitochondrial enzyme cis-
aconitate decarboxylase found in both stimulated and unstimu-
lated macrophages. Itaconate has been reported to be both an
antimicrobial metabolite and an immunomodulator, but its exact
physiologic role has remained enigmatic and is of growing in-
terest (12–17). Mtb elicits an immune response that leads to a
supraphysiological concentration (millimolar range) of itaconate
in macrophages; itaconate inhibits the bacterial isocitrate lyase, a
key enzyme in the glyoxylate shunt that is known to be associated
with bacterial pathogenesis (12, 18, 19). A canonical itaconate
dissimilation pathway has been described in vitro and ex vivo in
mammalian mitochondria and in bacteria such as Micrococcus
sp., Salmonella sp., Pseudomonas sp., and Yersinia sp. In these
bacteria, itaconate dissimilation involves the activation of itac-
onate with succinyl-CoA to form itaconyl-CoA, catalyzed by a
CoA transferase, followed by stereo-specific hydration to form
(S)-citramalyl-CoA, catalyzed by a hydratase, and subsequently
carbon–carbon bond cleavage to form pyruvate and acetyl-CoA
(Ac-CoA), catalyzed by a lyase (20–24). Logically, due to the
significant chemical structural resemblance of itaconate and
CoA-thioester intermediates to TCA cycle metabolites and en-
dogenous CoA thioesters, we inferred that Mtb might possess an
itaconate dissimilation pathway, composed of a currently un-
identified transferase, hydratase, and lyase. If such pathway ex-
ists in Mtb, as an intracellular pathogen, it might take advantage
of the high concentration of itaconate present in macrophages
and use itaconate as a carbon source (3, 4).
Mtb protein Rv2498c is currently annotated as the β-subunit
(CitE) of the heterotrimeric prokaryotic citrate lyase complex
involved in TCA cycle cataplerosis (25–27). However, the genes
encoding the associated α- and γ-subunits of the citrate lyase
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complex are absent in the Mtb genome, suggesting a different but
related function (25, 28). Bona fide CitE enzymes catalyze the
cleavage of (3S)-citryl-CoA to Ac-CoA and oxaloacetate (Enzyme
Commission [EC] 4.1.3.34), thus Rv2498c is most probably also a
short-chain acyl-CoA lyase but of unknown substrate specificity and
physiologic role.
Combining phylogenetic analysis, in vitro enzymatic assays, in
vivo Mtb experiments, and X-ray crystallography, we identi-
fied Mtb Rv2498c as an essential stereospecific bifunctional
β-hydroxyacyl-CoA lyase (β-HAC lyase) that carries out the last
step of itaconate dissimilation pathway and confers resistance to
itaconate. Overall, these findings offer insights into the biology
and physiological plasticity of Mtb.
Results
Phylogenetic Analysis Identifies Two Putative Mtb Lyases. Rv2498c is
reported to encode the β-subunit of citrate lyase complex (CitE),
but the associated α- and γ-subunits needed to form the functional
citrate lyase complex appear to be absent in Mtb and, thus, this
annotation is likely incorrect (7, 25). Aiming to conduct a com-
prehensive comparison of Rv2498c in the context of related en-
zymes, we constructed an amino acid sequence phylogenetic tree
of the Pfam HpcH/HpaI aldolase/citrate lyase family (PF03328; SI
Appendix, Fig. S1) (29). A variety of enzymatic activities have been
described for PF03328 members, but the majority fall into 2 clas-
ses: aldehyde lyases (EC 4.1.2) and oxoacid lyases (EC 4.1.3);
Rv2498c belongs to the latter. Rv2498c and a paralog, Rv3075c,
have recently been described by Arora et al. (30) as essential
enzymes for Mtb to establish infection in human THP-1
macrophages and guinea pigs. Despite that, substrates and phys-
iologic role of both enzymes remain unknown.
Our phylogenetic analysis suggests that broad substrate spec-
ificity and multiple related enzymatic reactions involving analogs
of β-hydroxyl-positioned CoA-thioesters (e.g., HMG-CoA,
malyl-CoA, β-methylmalyl-CoA, and citramalyl-CoA) are com-
mon features in the PF03328 family. Partial phylogenetic cov-
erage, broad substrates specificity, and multiple reactions make
functional assignment based on bioinformatics alone unreliable.
The substrates and enzymes identified are involved in a variety of
pathways including leucine catabolism, itaconate dissimilation,
glyoxylate shunt, acetate assimilation, carbon dioxide fixation,
C1 assimilation via the serine cycle and via the ethylmalonyl-
CoA pathway, C2 assimilation via the ethylmalonyl-CoA path-
way, and the methylaspartate pathway (20, 31–34).
Rv2498c Is Not an (S)-Citryl-CoA Lyase. The (S)-citryl-CoA lyase
activity initially attributed to Rv2498c was directly tested using
an ultraviolet-visible (UV-Vis) high-performance liquid chro-
matography (HPLC)-based assay. We synthesized (S)-citryl-CoA
from inactivated citrate lyase as previously described by Buckel
et al. (35) and confirmed that Rv2498c is unable to cleave (S)-
citryl-CoA (SI Appendix, Fig. S2). In strict agreement with our
results using recombinant enzyme, we found that (S)-citryl-CoA
is readily hydrolyzed using cell-free protein extracts (CFPEs)
derived from both Mtb H37Rv (parent) and from an rv2498c-
knockout (Δrv2498c) strain (SI Appendix, Fig. S2), confirming
that Rv2498c is not the enzyme responsible for (S)-citryl-CoA
hydrolysis.
Rv2498c Is an (S)-Citramalyl-CoA Lyase. Motivated by the results of
the phylogenetic analysis, we tested whether (S)-citramalyl-CoA
is a substrate for Rv2498c by UV-Vis HPLC. (S)-Citramalyl-CoA
was found to be a substrate for Rv2498c. Rv2498c catalyzed the
carbon–carbon bond cleavage of (S)-citramalyl-CoA to form
pyruvate and Ac-CoA (kcat/Km = 2.3 × 10
5; Fig. 1A and Table 1).
The identity of Rv2498c reaction substrate and products was
confirmed by comparing HPLC retention times and mass to
charge ratios (m/z) to those of standards: (S)-citramalyl-CoA,
Ac-CoA, and pyruvate (Fig. 1B and SI Appendix, Fig. S3).
To validate the results obtained using purified recombinant
Rv2498c, we investigated the carbon–carbon cleavage of (S)-
citramalyl-CoA using CFPEs from parent, Δrv2498c, and an
rv2498c-complemented strain where the rv2498c gene is present
elsewhere in the chromosome (Δrv2498c::rv2498c). The results
using CFPEs were consistent with the results using recombinant
Rv2498c, i.e., parent strain and complement strain CFPEs, but not
Δrv2498c strain CFPE, degraded (S)-citramalyl-CoA (Fig. 1B).
Rv2498c Is an (R)-HMG-CoA Lyase. Our phylogenetic analysis also
prompted us to screen a diverse panel of commercially available
CoA-thioesters (SI Appendix, Table S1). In this screen, incubation
of Rv2498c with HMG-CoA generated a product with a retention
time similar to Ac-CoA and consumed exactly half of the
HMG-CoA racemic mixture, suggesting absolute stereospecificity
(kcat/Km = 3.9 × 10
5; Table 1, Fig. 2 A–C, and SI Appendix, Fig. S4);
the stereoisomer (S)-HMG-CoA is a known metabolic intermediate
in the leucine catabolic pathway, which is incompletely annotated in
Mtb (36). To unambiguously determine the stereospecificity of
Rv2498c for HMG-CoA, we eliminated either the (R)- or (S)-
isomer of HMG-CoA from the reaction mixture by taking ad-
vantage of the known stereospecific HMG-CoA lyases from
Pseudomonas aeruginosa, PA0883 and PA2011 (20). Interestingly,
Fig. 1. Rv2498c and Mtb CFPE degrade (S)-citramalyl-CoA. (A) Rv2498c (S)-
citramalyl-CoA lyase reaction scheme. (B) HPLC chromatograms of (S)-
citramalyl-CoA incubated with or without recombinant Rv2498c or Mtb
CFPEs, and standards for Ac-CoA and pyruvate-phenylhydrazone. Pyruvate
was derivatized with phenylhydrazine for UV-Vis detection at 324 nm.
Degradation of (S)-citramalyl-CoA is not observed in the Δrv2498c CFPE
chromatogram, indicating that Rv2498c is needed for the activity.
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we found that Rv2498c is a lyase specific for the (R)-HMG-CoA
isomer. Based on the observation that Ac-CoA is one product, the
other likely product of C-C bond cleavage is acetoacetate (AAc),
which is not visible in our UV-Vis HPLC assay. To directly detect
the formation of AAc, we analyzed the reaction products by
1H-Nuclear Magnetic Resonance (NMR) spectroscopy and ob-
served the formation of Ac-CoA and AAc from half of the (R/S)-
HMG-CoA in the reaction mixture (Fig. 2D). These results
demonstrated the stereospecific (R)-HMG-CoA lyase activity
of Rv2498c.
We also investigated the stereochemical course of HMG-CoA
degradation in Mtb CFPE. Consistent with the results obtained
using recombinant Rv2498c, parent and complement strains
CFPEs, but not Δrv2498c CFPE, degraded (R)-HMG-CoA (Fig.
2C). These results (i) confirmed the (R)-specific stereochemical
course of HMG-CoA degradation in Mtb, (ii) demonstrated that
Rv2498c is both necessary and sufficient for the breakdown of
the (R)-HMG-CoA, and (iii) suggested that (R)-HMG-CoA is
the only isomer present in Mtb.
Rv2498c Also Displays Weak Malate/Methylmalate Synthase Activity
In Vitro. Unexpectedly, Rv2498c was also found to catalyze the
hydrolysis of the thioester bond of (S)-malyl-CoA and β-meth-
ylmalyl-CoA in vitro (SI Appendix, Fig. S5). (S)-Malyl-CoA is the
in situ condensation reaction product of glyoxylate and Ac-CoA
in the glyoxylate shunt, while β-methylmalyl-CoA is the con-
densation product of glyoxylate and propionyl-CoA in the 3-
hydroxypropionate pathway of CO2 assimilation. Rv2498c
malate/methylmalate synthase activity was observed in vitro us-
ing Ac-CoA and propionyl-CoA and an excess quantity of
glyoxylate. We determined the kinetic parameters for the re-
action and found that Rv2498c is not catalytically comparable to
the bona fide malate synthase GlcB (Rv1837c), and these ac-
tivities are much slower than the reactions with (R)-HMG-CoA
or (S)-citramalyl-CoA (Table 1) (37, 38). The methylmalate
synthase activity is not expected to be relevant in vivo as Mtb is
not known to possess a 3-hydroxypropionate pathway (31).
From our in vitro results, we have shown that Rv2498c has
β-hydroxyl-acyl-CoA lyase and thioesterase activities, and that (R)-
HMG-CoA, (S)-citramalyl-CoA, (S)-malyl-CoA, and β-methylmalyl-
CoA, but not (S)-citryl-CoA, are Rv2498c substrates. These results
unambiguously establish that Rv2498c is not a CitE.
Rv2498c Participates in Itaconate Dissimilation and L-leucine Catabolism
in Mtb.We interrogated the role of Rv2498c in Mtb metabolism by
comparing growth and metabolic profiles of Δrv2498c, parent, and
Δrv2498c::rv2498c complement strains. These 3 strains were cul-
tured in chemically defined media of composition similar to Mid-
dlebrook 7H10 agar medium but with a single carbon source
present. In accordance to our substrate specificity results using
recombinant Rv2498c and CFPEs, we hypothesized that Rv2498c
could be involved in itaconate dissimilation, a process that involves
Table 1. Catalytic properties of recombinant β-HAC lyase and







Rv2498c: β-Hydroxyacyl-CoA lyase activity
(R)-HMG-CoA — 36 ± 3 90 ± 22 3.9 × 105
(S)-Citramalyl-CoA — 21 ± 2 75 ± 19 2.3 × 105
Rv2498c: malate/methylmalate synthase activity
Ac-CoA Glyoxylate 0.15 ± 0.04 2,124 ± 200 6.9 × 101
Pro-CoA Glyoxylate 0.08 ± 0.03 729 ± 163 1.1 × 102
Rv1837c: malate synthase activity
Ac-CoA Glyoxylate 76 ± 4 45 ± 9 1.7 × 106
Fig. 2. Rv2498c is a stereospecific lyase that cleaves (R)-HMG-CoA to produce
Ac-CoA and acetoacetate. (A) Rv2498c (R)-HMG-CoA lyase reaction scheme. (B)
HPLC chromatograms of HMG-CoA racemic mixture incubated with recombi-
nant Rv2498c. The (R)-HMG-CoA lyase stereospecificity of Rv2498c is revealed
when adding to the reaction either (R)-HMG-CoA-specific lyase Pa0883 or (S)-
HMG-CoA-specific lyase Pa2011. Rv2498c with Pa0883 only consumed half of
HMG-CoA, while Rv2498c with Pa2011 consumed all HMG-CoA. (C) HPLC
chromatograms of HMG-CoA incubated with Mtb CFPEs with or without (S)-
HMG-CoA-specific lyase Pa2011. Degradation of (R)-HMG-CoA is not observed
in the Δrv2498c CFPE chromatogram, indicating that Rv2498c is needed for the
activity. (D) Comparison between the 1H NMR spectra of HMG-CoA incubated
with or without recombinant Rv2498c and standards for Ac-CoA and aceto-
acetate. Peaks assigned to Ac-CoA –CH3 (iii) group and acetoacetate –CH3 (v)
and –CH2– (iv) groups are only observed in the spectrum with Rv2498c.








(S)-citramalyl-CoA formation (Fig. 3A), and in L-leucine catabo-
lism, in which (R)-HMG-CoA is a catabolic intermediate (Fig. 4A).
A growth defect was observed for Δrv2498c compared with
parent and complemented strains on agar medium in the pres-
ence of itaconate as the sole carbon source (Fig. 3B). A pathway
for itaconate degradation has not been described for Mtb, but in
mammals and in some bacteria, it is thought to proceed via ac-
tivation of itaconate to itaconyl-CoA, stereospecific hydration to
form (S)-citramalyl-CoA, and C-C bond cleavage to form pyru-
vate and Ac-CoA (Fig. 3A) (20–23). Consistent with the exis-
tence of this pathway in Mtb and with the involvement of
Rv2498c in itaconate degradation, we observed accumulation of
citramalate, the hydrolysis product of citramalyl-CoA, in the
Δrv2498c strain when grown in itaconate as the sole carbon
source, as observed using liquid chromatography-mass spec-
trometry (LC-MS) (Fig. 3C). To unambiguously demonstrate
that the observed citramalate is directly derived from itaconate,
we employed (U)-13C-itaconate as the sole carbon source.
Confirming our hypothesis, the citramalate accumulating under
these conditions was universally labeled (M+5) (Fig. 3D).
Furthermore, consistent with a role of Rv2498c in L-leucine
metabolism, no growth was observed on agar medium for the
Δrv2498c strain in the presence of L-leucine as the sole carbon
source compared with parent and complemented strains on agar
medium (Fig. 4B). We inferred that this growth deficiency was
likely the outcome of the absence of HMG-CoA lyase activity,
resulting in the accumulation of HMG, limited production of Ac-
CoA, and/or altered branched-lipid metabolism. Accordingly, in
the presence of L-leucine as the sole carbon source, Δrv2498c, but
not the parent or the complemented strains, accumulated HMG,
as well as other leucine catabolism intermediates such as meth-
ylcrotonate, methylglutaconate, and hydroxymethylglutarate, as
observed using LC-MS (Fig. 4C).
These in vivo experiments corroborated our in vitro and ex
vivo biochemical data and offer further evidence that Rv2498c is
a bifunctional enzyme participating in itaconate dissimilation
and leucine catabolism in Mtb.
The MtbΔrv2498c Strain Is Attenuated in a Mouse Aerosol Infection
Model.To test the impact of rv2498c deletion during infection, we
carried out a low-dose aerosol infection of C57BL/6J mice, a
Fig. 3. Rv2498c participates in itaconate dissimilation in Mtb. (A) The proposed pathway for itaconate dissimilation. (B) Agar medium Mtb spotting culture
after 25 d on 10 mM itaconate as the sole carbon source. Mtb Δrv2498c failed to grow on itaconate compared with parent and complement strains. The
results are representative of 3 independent experiments. Metabolite profile of Mtb filter culture after 17-h exposure to agar medium with 10 mM itaconate
(C) or 15 mM [13C5]-itaconate (D) as the sole carbon source. The metabolite profile shows the accumulation of itaconate/M+5 and citramalate/M+5 (from
hydrolyzed citramalyl-CoA) in the Mtb Δrv2498c metabolite extract. The data are shown as mean values ± SD from 3 independent experiments.
Fig. 4. Rv2498c participates in L-leucine catabolism in Mtb. (A) The proposed pathway for L-leucine catabolism. (B) Agar medium Mtb spotting culture after
25 d on 10 mM L-leucine as the sole carbon source. Mtb Δrv2498c failed to grow on L-leucine compared with parent and complement strains. The results are
representative of 3 independent experiments. (C) Metabolite profile of Mtb filter culture after 17-h exposure on 10 mM L-leucine as the sole carbon source
agar medium. The metabolite profile shows the accumulation of leucine, methylcrotonate (hydrolyzed product), methylglutaconate (hydrolyzed product),
and HMG (from hydrolyzed HMG-CoA) in the Mtb Δrv2498c metabolite extract. The data are shown as mean values ± SD from 3 independent experiments.
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mouse strain widely used in experimental TB research studies.
The MtbΔrv2498c strain resulted in at least one log10 reduction
in colony forming units in the lung at days 28, 84, and 112 after
infection compared with the parent strain (SI Appendix, Fig. S6).
The attenuation observed for the Δrv2498c strain suggests that
one or more of the activities associated with Rv2498c have a sig-
nificant negative impact on the fitness of Mtb during experimental
infection.
Rv2498c (S)-Citramalyl-CoA Bound Structure Reveals the Molecular
Basis for Stereospecificity. To investigate the molecular basis of
Rv2498c substrate stereospecificity for the carbon–carbon bond,
we determined the structures of Rv2498c in a variety of liganded
states by X-ray crystallography (SI Appendix, Table S2). All
structures obtained showed the same trimeric arrangement of
protomers previously described for the unliganded structure and
for the oxaloacetate- and Mg2+-bound structure (25). In contrast
to the previously reported structures, the C terminus (50 resi-
dues) is well ordered in our structures, forming an α-helix/
β-hairpin/α-helix motif that packs against the surface of the
neighboring protomer, capping its active site (SI Appendix, Fig.
S7A). The fact that the C terminus is ordered in these ligand-
bound structures is consistent with earlier observations that the
position and organization of the C terminus might depend on the
occupancy of the active site (SI Appendix, Fig. S7B) (33).
Rv2498c has no sequence and modest structural similarity to
the characterized family of TIM barrel (S)-HMG-CoA lyases
that include human HMG-CoA lyase (Protein Data Bank [PDB]
ID code 3MP5) and the bacterial lyases from Brucella melitensis,
Bacillus subtillis, and P. aeruginosa (PDB ID codes 1YDN,
1YDO, and 2FTP) (39). Instead, the 3 most closely related
ligand-bound structures to Rv2498c are the human citramalyl-
CoA lyase CLYBL (PDB ID code 5VXO) and the bacterial
L-malyl-CoA/β-methylmalyl-CoA lyases from Rhodobacter sphaer-
oides (PDB ID code 4L9Y) and from Chloroflexus aurantiacus
(PDB ID code 4L80) with RMSDs of 2.35 (over 261 Cα atoms),
2.43 (over 266 Cα atoms), and 2.65 (over 266 Cα atoms), re-
spectively (14, 33, 40, 41). These 3 proteins were crystallized with
propionyl-CoA in their active sites.
The Rv2498c structures presented here are complexes with
(S)-citramalyl-CoA (PDB ID code 6AQ4) and with acetoaceta-
te:CoA (PDB ID code 6AS5). The CoA moiety binds in a deep
cleft at the base of which resides the active site Mg2+ ion. The
Mg2+ ion is coordinated by the 3-hydroxyl group and by an
unidentate interaction with the terminal carboxylate of the li-
gand, as well as by Glu112, Asp138, and 2 water molecules (Fig.
5 A and B). The carboxylate of the substrate is further positioned
by polar interactions with the backbone NH atoms of Ala136,
Glu137, and Asp138, while the 3-hydroxyl group lies close to
Arg64. The 3-methyl group of the ligand contacts a hydrophobic
surface formed by Gly135 and the side-chain atoms of Met133 and
Val181 (SI Appendix, Fig. S8). Of note, the structure with (S)-
citramalyl-CoA bound was obtained from crystals that were
soaked with pyruvate and Ac-CoA, therefore indicating that the
conformation of Rv2498c in the crystals is catalytically active.
Because the citramalyl group observed in the active site was in the
S configuration, which corresponds to the R configuration at the 3-
position of HMG-CoA (SI Appendix, Fig. S9), we modeled the mode
of binding of (R)-HMG-CoA to further understand the molecular
basis for the (S)-HMG-CoA lyase associated with mammalian
L-leucine catabolism. In this case, the additional methylene unit (C4)
found in HMG-CoA is readily accommodated in the active site and
can support a less distorted octahedral coordination of the Mg2+ ion
(the bite angle of the citramalyl group is ∼70°; the modeled HMG
moiety bite angle is ∼85°). Likewise, Molprobity calculations
revealed shape and charge complementarity between the protein
and modeled substrate, consistent with the active site supporting
energetically favorable interactions with (R)-HMG-CoA (42). At-
tempts to model (S)-HMG-CoA into the active site generated
electrostatically unfavorable interactions. Interestingly, with
respect to the human (S)-HMG-CoA lyase (Fig. 5C, PDB ID
code 3MP5), the differential positioning of the Mg2+ ion co-
ordination with conserved Asp and Glu residues in the active
site contributes to the stereoselectivity between the HMG-CoA
stereoisomers.
Discussion
Mtb is highly adapted to the human host and is physiologically
resilient. We show that Mtb can dissimilate itaconate, a macro-
phage metabolite produced during host inflammatory response to
fight infection (12, 14, 15). In contrast to the established antimi-
crobial character of this molecule, itaconate is present in some
prokaryotes (12, 14–17, 20, 21, 23, 43, 44). Moreover, our results
suggest that Mtb can catabolize itaconate via a noncanonical
dissimilation pathway. Itaconate dissimilation in Mtb involves the
bifunctional enzyme Rv2498c, which cleaves (S)-citramalyl-CoA
Fig. 5. Ligand-bound X-ray 3D structures of Rv2498c reveal that metal co-
ordination is the basis of stereoselectivity. (A) Close-up view of the catalytic site
and a representation of (S)-citramalyl-CoA-bound Rv2498c (PDB ID code 6AQ4).
The β-hydroxyl group chelation of the Mg2+ ion favors the S-conformation of
citramalyl-CoA. (B) Close-up view of the catalytic site of acetoacetate-bound
Rv2498c (PDB ID code 6AS5), and a representation of (R)-HMG-CoA in
Rv2498c was modeled based on the reaction substrate (S)-citramalyl-CoA (A)
and the reaction product acetoacetate. Acetoacetate, the HMG-CoA carbon–
carbon cleavage product retains the keto-acid conformation. (C) Close-up
view of the catalytic site and a representation of human (S)-HMG-CoA lyase
R41M mutant (PDB ID code 3MP5) bound to (S)-HMG-CoA is shown for com-
parison. Ribbon and stick representations were generated using PyMOL and
ChemDraw. Atoms are colored according to the CPK coloring scheme. *, a chiral
carbon center. Blue spheres represent water molecules and green spheres
represent Mg2+ ions.








producing Ac-CoA and pyruvate, effectively using a host-derived
antibacterial molecule as a nutrient source.
We show that Mtb catabolizes L-leucine via an unprece-
dented use of (R)-HMG-CoA rather than the commonly attributed
(S)-HMG-CoA isomer. Mtb lacking Rv2498c appears to suffer the
same fate as humans with HMG-CoA lyase-deficiency, the accu-
mulation of HMG and keto acids from the leucine catabolic
pathway (45). In addition to L-leucine, we tested L-valine and
L-isoleucine (the 2 other branched-chain amino acids) and observed
no differences in growth phenotypes between the parent and the
Δrv2498c strains. These results agree with the known differences in
the catabolism of these 3 amino acids; HMG-CoA is produced
during L-leucine degradation and not a shared metabolic in-
termediate in the catabolism of branched-chain amino acids.
We also found that Rv2498c could function as a malate/
methylmalate synthase, albeit with low efficiency, by catalyzing
an aldol condensation followed by thioester hydrolysis of (S)-
malyl-CoA or β-methylmalyl-CoA, resulting in the formation of
malate from glyoxylate and Ac-CoA, or methylmalate from
glyoxylate and propionyl-CoA, respectively. The physiologic role
for Rv2498c as a putative synthase/thioesterase is unclear as Mtb
possesses a bona fide malate synthase (GlcB, Rv1837c) (38, 46).
However, the first step in the glyoxylate shunt is also catalyzed by
2 apparently redundant isocitrate lyases (Rv0467 and Rv1915-
Rv1916). Although there is no known metabolic pathway in Mtb
which uses β-methylmalyl-CoA, Rv2498c could act to detoxify
glyoxylate and propionyl-CoA from odd chain lipid catabolism
under glyoxylate shunt metabolic state (46). Nonetheless, such
potential redundancy might be metabolically advantageous if the
enzymes display different kinetic or regulatory properties in vivo.
It is also possible that multifunctional enzymes, such as Rv2498c,
allow for circumvention in the presence of enzyme inhibitors of
the canonical enzymes (31, 46, 47).
Our crystal structures for full-length Rv2498c shed light into
the molecular basis of substrate specificity and stereoselectivity
for (S)-citramalyl-CoA and revealed how the C-terminal domain
interacts directly with the neighboring CoA substrate, therefore
playing an important role in substrate binding selectivity. We
suggest that Rv2498c carbon–carbon cleavage of (S)-citramalyl-
CoA follows a mechanism similar to that proposed for (S)-
HMG-CoA lyase described by Fu et al. (48) (SI Appendix, Fig.
S10) and that the difference in the (S)- and (R)-stereospecificity
for HMG-CoA can be partially attributed to the β-positioned
hydroxyl group of the CoA-thioester coordination with the di-
valent metal. We observed that the Rv2498c catalytic site has
ordered water molecules, suggesting a catalytic mechanism for the
carbon–carbon cleavage with water participation by shuttling
protons and/or acting as the nucleophile during hydrolysis (33, 48,
49). The lyase reaction likely proceeds via the reversal of standard
retro-aldol condensation, as previously suggested (48, 50).
In conclusion, we found Rv2498c, which we renamed as a bi-
functional β-HAClyase, in a class of oxoacid lyases with paradoxical
features: characterized by mild promiscuity for substrates but ab-
solute discrimination on the substrate stereochemistry. A systematic
evaluation of substrate specificity revealed (R)-HMG-CoA ∼ (S)-
citramalyl-CoA >>> (S)-malyl-CoA ∼ β-methylmalyl-CoA as sub-
strates for Rv2498c. Our results demonstrate that Mtb possesses the
ability to dissimilate itaconate and an (R)-specific HMG-CoA
L-leucine catabolic pathway. We further elucidated the enzymatic
activities of Rv2498c as a β-HAClyase and presented a full-length
crystal structures of the protein, which revealed the details of its
substrate stereospecificity and the involvement of the C-terminal
domain in acyl-CoA binding. Importantly, deletion of rv2498c
from the Mtb genome led to a defect during murine infection, in-
dicating that one or more of its enzymatic functions are important
during infection. Our work further highlights that understanding of
even the most well conserved and central metabolic pathways in
Mtb is hampered by the prevalence in the genome of experimentally
uncharacterized enzymes and enzymatic function database mis-
annotations. Mtb Rv2498c is a striking example of an enzyme that
eluded functional characterization for over a decade, highlighting
the intricacies and difficulties of enzyme functional assignment.
Materials and Methods
All biological and chemical reagents were purchased from Sigma-Aldrich or
Fisher Scientific, unless stated otherwise. Minimal media of chemically defined
formulae were prepared in-house. pML1335-GFP or pML1357 was a gift from
Michael Niederweis (Addgene plasmid 32378; http://www.addgene.org/32378/;
RRID:Addgene_32378). A full description of methods for gene cloning, pro-
tein expression and purification, phylogenetic analysis, Mtb growth conditions,
enzyme assays, murineMtb aerosol infections, metabolomics, HPLC, LC-UV/MS,
and X-ray data collection and analysis are described in SI Appendix.
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